A population-based study of the use of radium 223 in metastatic castration-resistant prostate cancer: Factors associated with treatment completion

摘要

IntroductionRadium 223 (Ra223) given for six cycles has proven efficacy in clinical trials, but its population-level generalizability has not been well-described. The objectives of this study were to describe population-based Ra223 use in the abiraterone and enzalutamide era and identify factors associated with completion.